Lawsuit Alleges Securities Fraud by Aardvark Therapeutics
Investors who lost money in Aardvark Therapeutics, Inc. (AARD) have the opportunity to lead a securities fraud class action lawsuit. The lawsuit alleges misleading statements regarding the company's drug development.
BENSALEM TOWNSHIP, Pa. – September 25, 2026 – The Law Offices of Howard G. Smith announced that investors who sustained substantial losses in Aardvark Therapeutics, Inc. (AARD) have an opportunity to lead a securities fraud class action lawsuit.
The complaint alleges that between February 10, 2025, and May 14, 2026, defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business, operations, and prospects. Specifically, the lawsuit claims that the company misrepresented the safety of its drug candidate, ARD-101, and overstated its clinical, regulatory, and commercial prospects.
Investors who purchased Aardvark Therapeutics securities during the specified period and suffered losses are encouraged to contact the Law Offices of Howard G. Smith before the lead plaintiff deadline of October 13, 2026. The law firm is seeking individuals to potentially lead the class action.
The lawsuit seeks to recover damages on behalf of investors. Potential class members do not need to take any action at this time to remain part of the lawsuit but may retain counsel of their choice.